Verona Pharma names new CFO
This article was originally published in Scrip
Executive Summary
London-based Verona Pharma, which develops treatments for respiratory diseases, has named Richard Bungay chief financial officer – effective 5 September 2013. Mr Bungay is also part-time CEO of Chroma Therapeutics, a venture capital-backed biotechnology company developing novel small molecules for inflammation and oncology. He succeeds Danny Lowe in the position. Mr Lowe, who is based in Canada, will continue to work with Mr Bungay for an interim handover period.